Bottom line
DEECX vs BAGIX: the short answer
DEECX (Nomura Extended Duration Bond Fund) and BAGIX (Baird Aggregate Bond Fund) are both mutual funds.
But BAGIX is far broader, holding 2,061 positions to 183 for DEECX, so beyond the top names it adds exposure DEECX doesn't have.
BAGIX is cheaper at 0.3% vs 1.56% — a difference of $126 a year per $10,000 invested.
Over five years, BAGIX returned −0.1% a year vs −2.9% for DEECX (reporting dates differ).
Updated Nov 19, 2026
DEECX vs BAGIX side by side
| DEECX | BAGIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Voya | Baird |
| Category | Core / Intermediate Bond | Core / Intermediate Bond |
| Expense ratio | 1.56% | 0.3% |
| Annual cost per $10k | $156 | $30 |
| 10-yr cost on $10k (prospectus) | $2,037 | $381 |
| Max front load | 0% | — |
| 12b-1 fee | 1% | 0% |
| 1-yr return | −3.3% | +7.4% |
| 5-yr return (annualized) | −2.9% | −0.1% |
| 10-yr return (annualized) | +0.7% | +2.4% |
| Best quarter | — | +7.2% |
| Worst quarter | — | −6.3% |
| Net assets (fund) | $242.1M | $57.9B |
| Number of holdings | 183 | 2,061 |
| Portfolio turnover | 119% | 34% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
DEECX and BAGIX share none of their top holdings.
DEECX top 10
- T-mobile USA Inc — 1.77%
- At&t Inc — 1.61%
- Amgen Inc — 1.60%
- Boeing Company (the) — 1.60%
- Union Pacific Corp — 1.59%
- Wells Fargo & Company — 1.50%
- Jp Morgan Chase & Company — 1.30%
- Lockheed Martin Corp — 1.29%
- Thermo Fisher Scientific Inc — 1.28%
- Elevance Health Inc — 1.24%
BAGIX top 10
- US Treasury N/b — 2.30%
- First American Government Obli — 2.13%
- US Treasury N/b — 1.99%
- US Treasury N/b — 1.46%
- US Treasury N/b — 1.40%
- US Treasury N/b — 1.34%
- US Treasury N/b — 1.27%
- US Treasury N/b — 1.19%
- US Treasury N/b — 1.17%
- US Treasury N/b — 1.13%
FAQ
What is the difference between DEECX and BAGIX?
Which is cheaper, DEECX or BAGIX?
Should I own both DEECX and BAGIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.